SG11201407775WA - Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta - Google Patents

Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta

Info

Publication number
SG11201407775WA
SG11201407775WA SG11201407775WA SG11201407775WA SG11201407775WA SG 11201407775W A SG11201407775W A SG 11201407775WA SG 11201407775W A SG11201407775W A SG 11201407775WA SG 11201407775W A SG11201407775W A SG 11201407775WA SG 11201407775W A SG11201407775W A SG 11201407775WA
Authority
SG
Singapore
Prior art keywords
international
metabolic syndrome
street
methods
hsp
Prior art date
Application number
SG11201407775WA
Inventor
Niven Rajin Narain
Rangaprasad Sarangarajan
Vivek K Vishnudas
Enxuan Jing
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of SG11201407775WA publication Critical patent/SG11201407775WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/177535 A2 (51) International Patent Classification: A61K 48/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/042692 24 May 2013 (24.05.2013) English English (30) Priority Data: 61/652,023 25 May 2012 (25.05.2012) (84) US (71) Applicant: BERG PHARMA LLC [US/US]; 1845 Elm Hill Pike, Nashville, TN 37210 (US). (72) Inventors: NARAIN, Niven, Rajin; 73 Fresh Pond Park­ way, Cambridge, MA 02138 (US). SARANGARAJAN, Rangaprasad; 45 Central Street, Boylston, MA 01505 (US). VISHNUDAS, Vivek, K.; 91 Stamford Street, Apt. 1, Newton, MA 02466 (US). JING, Enxuan; 200 Maple Street, West Roxbury, MA 02132 (US). (74) Agents: HANLEY, Elizabeth, A. et al.; Mccarter & Eng­ lish, LLP, 265 Franklin Street, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90- BETA Delta-Delta Networks DD_NG.vs.HG.vs.HGT 1 ,cys [ NG vs. HG ] vs. [ HS vs. HGT1 ] CJ m i> i> T-H rn T-H O (57) Abstract: The invention provides methods of treatment of metabolic syndrome with HSP90 inhibitors, particularly HSP90P in- ^ hibitors. The invention provides methods of diagnosis and monitoring of metabolic syndrome using HSP90, particularly HSP90p, Q expression and activity level.
SG11201407775WA 2012-05-25 2013-05-24 Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta SG11201407775WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261652023P 2012-05-25 2012-05-25
PCT/US2013/042692 WO2013177535A2 (en) 2012-05-25 2013-05-24 Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta

Publications (1)

Publication Number Publication Date
SG11201407775WA true SG11201407775WA (en) 2014-12-30

Family

ID=49624539

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407775WA SG11201407775WA (en) 2012-05-25 2013-05-24 Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta

Country Status (15)

Country Link
US (2) US9533002B2 (en)
EP (1) EP2854865B1 (en)
JP (1) JP6478908B2 (en)
KR (1) KR20150010793A (en)
CN (1) CN104812898B (en)
AU (1) AU2013266086B2 (en)
BR (1) BR112014029301A2 (en)
CA (1) CA2874676A1 (en)
EA (1) EA201492184A1 (en)
HK (1) HK1209035A1 (en)
IL (1) IL235910A0 (en)
MX (1) MX2014014188A (en)
NZ (1) NZ702169A (en)
SG (1) SG11201407775WA (en)
WO (1) WO2013177535A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104812898B (en) * 2012-05-25 2018-01-30 博格有限责任公司 The method for treating metabolic syndrome by adjusting the β of heat shock protein (HSP) 90
RU2768868C2 (en) 2012-09-27 2022-03-25 Дзе Чилдрен'З Медикал Сентер Корпорейшн Compounds for treating obesity, and methods for using them
AU2015235979B2 (en) * 2014-03-26 2019-05-02 The Children’s Medical Center Corporation Celastrol and derivatives for the treatment of obesity
US10023864B2 (en) 2014-06-06 2018-07-17 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
US10336768B2 (en) 2014-06-13 2019-07-02 Yuma Therapeutics, Inc. Pyrimidine compounds and methods using the same
EP3271005A4 (en) * 2015-03-19 2018-09-05 Old Dominion University Synergistic regulated cell death induction with hsp90 inhibitors and nanosecond pulsed electric fields
JP7034078B2 (en) 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド Celastrol analogue
CN105920018B (en) * 2016-06-15 2019-01-11 上海市内分泌代谢病研究所 Celastrol combines the purposes of jamaicin preparation treatment antiobesity agents
CN107543929A (en) * 2016-06-23 2018-01-05 中国医学科学院肿瘤医院 Kit based on protein marker HSP90AB1 diagnosing patients
CN107028953A (en) * 2017-03-27 2017-08-11 北京大学 A kind of stimulant of sympathetic activity
TWI782982B (en) * 2017-04-24 2022-11-11 美商薩沐斯醫療公司 Hsp90 inhibitor oral formulations and related methods
WO2018235251A1 (en) 2017-06-23 2018-12-27 株式会社ニコン Analysis device, analysis program, and analysis method
CN112156188A (en) * 2020-11-10 2021-01-01 上海交通大学医学院附属瑞金医院 Application of Hsp90 in preparation of drugs for preventing and treating steroid diabetes
CN113332308A (en) * 2021-02-22 2021-09-03 广东省妇幼保健院 Application of preparation for regulating HSP90B1 expression level in preparation of medicine for preventing or treating polycystic ovarian syndrome
CN113160983A (en) * 2021-04-09 2021-07-23 南京医科大学附属逸夫医院 Metabolism-related fatty liver disease clinical prediction model

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078375B1 (en) * 1996-10-25 2006-07-18 Peter Mose Larsen Diabetes-mediating proteins and therapeutic uses thereof
US20040048256A1 (en) 2001-09-07 2004-03-11 Agee Michele L. Novel proteins and nucleic acids encoding same
CA2501577A1 (en) 2002-10-07 2004-04-22 Antigenics, Inc. Heat shock protein binding fragments of cd91, and uses thereof
WO2004072080A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
EP1675861B1 (en) 2003-08-29 2015-12-23 Vernalis (R&D) Ltd. Pyrimidothiophene compounds
WO2005115431A2 (en) 2004-05-24 2005-12-08 Adonia Papathanassiu Methods for inhibiting proteasome and heat shock protein 90
CN101137903A (en) * 2004-07-19 2008-03-05 罗彻斯特大学 Biomarkers of neurodegenerative disease
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
FR2885904B1 (en) 2005-05-19 2007-07-06 Aventis Pharma Sa NOVEL FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF
WO2007022042A2 (en) 2005-08-11 2007-02-22 Novartis Ag Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
US20070207950A1 (en) 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
WO2007097839A2 (en) 2006-02-16 2007-08-30 Massachusetts Eye And Ear Infirmary Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
US20100015126A1 (en) 2006-03-17 2010-01-21 Martijn Frans Ben Gerard Gebbink Methods of Binding of Cross-Beta Structures By Chaperones
KR20090019790A (en) 2006-05-19 2009-02-25 더 스크립스 리서치 인스티튜트 Treatment of protein misfolding
TW200804313A (en) 2006-05-25 2008-01-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
US7678803B2 (en) 2006-08-24 2010-03-16 Serenex, Inc. Quinazoline derivatives for the treatment of cancer
US20080070930A1 (en) 2006-08-24 2008-03-20 Huang Kenneth H Pyrimidine and Pyrazine Derivatives
EP2073802A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US9730912B2 (en) 2006-10-12 2017-08-15 Astex Therapeutics Limited Pharmaceutical compounds
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
JP2010509307A (en) 2006-11-09 2010-03-25 バイオチカ テクノロジー リミテッド 18,21-didesoxymacbecin derivatives for the treatment of cancer
WO2008094438A1 (en) 2007-01-26 2008-08-07 Kosan Biosciences Incorporated Macrolactams by engineered biosynthesis
RS52978B (en) 2007-03-20 2014-02-28 Curis, Inc. Fused amino pyridine as hsp90 inhibitors
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
WO2008151833A2 (en) 2007-06-13 2008-12-18 Hochschule Mannheim Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
IL184671A0 (en) 2007-07-17 2008-12-29 Hadasit Med Res Service Substances directed to heparanase c-terminal domain-or substance derived therefrom and uses thereof as modulators of heparanas biological activities
DE102007041116A1 (en) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-dihydro-isoindole derivatives
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
EP2060565A1 (en) 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
US20110218143A1 (en) 2007-11-20 2011-09-08 University Of Florida Research Foundation Compositions and methods for tissue repair
JP5582783B2 (en) 2007-12-28 2014-09-03 武田薬品工業株式会社 Screening method for cytoprotective agent
EP2262778B8 (en) * 2008-03-07 2020-01-01 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
WO2009114470A2 (en) 2008-03-10 2009-09-17 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
EP2100879A1 (en) 2008-03-13 2009-09-16 4Sc Ag Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
DE112008003876T5 (en) 2008-05-19 2013-06-06 Hewlett-Packard Development Co., L.P. Systems and methods for assisting a pre-boot logon
AU2009257635A1 (en) 2008-06-10 2009-12-17 Plexxikon, Inc. 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
WO2010014617A1 (en) 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
JP2011529941A (en) 2008-08-04 2011-12-15 ディーエスエム アイピー アセッツ ビー．ブイ． Method for producing carnosol from carnosic acid using hydrogen peroxide or peracid
WO2010019965A1 (en) 2008-08-15 2010-02-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection
US20110230551A1 (en) 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
KR101749353B1 (en) 2008-11-28 2017-06-20 노파르티스 아게 Pharmaceutical combination comprising a hsp90 inhibitor and a mtor inhibitor
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
EP2521594A2 (en) * 2010-01-07 2012-11-14 Akron Molecules GmbH Obesity small molecules
US20110201587A1 (en) * 2010-02-16 2011-08-18 Bio Holding, Inc. Hsp90 inhibitors and methods of use
AU2011216616A1 (en) 2010-02-17 2012-09-06 Ildong Pharm Co., Ltd. A novel 5-membered heterocycle derivatives and manufacturing process thereof
CA2697887A1 (en) 2010-03-12 2011-09-12 Institut De Recherches Cliniques De Montreal Modulating and/or detecting activation induced deaminase and methods of use thereof
WO2011133659A2 (en) 2010-04-20 2011-10-27 Emory University Inhibitors of hif and angiogenesis
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
US8598339B2 (en) 2011-02-01 2013-12-03 University Of Kansas Withanolide isolated from Physalis longifolia and analogs and methods of use thereof
WO2012139010A1 (en) 2011-04-08 2012-10-11 University Of Kansas Grp94 inhibitors
WO2013015661A2 (en) 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
CN104812898B (en) * 2012-05-25 2018-01-30 博格有限责任公司 The method for treating metabolic syndrome by adjusting the β of heat shock protein (HSP) 90
CN102772399A (en) * 2012-08-16 2012-11-14 厦门大学 Application of gambogic acid serving as protein kinase agonist activated by 5'-ampicillin (AMP)

Also Published As

Publication number Publication date
CN104812898A (en) 2015-07-29
KR20150010793A (en) 2015-01-28
MX2014014188A (en) 2015-05-11
AU2013266086B2 (en) 2018-03-01
EA201492184A1 (en) 2015-07-30
AU2013266086A1 (en) 2014-12-11
US9533002B2 (en) 2017-01-03
JP2015520170A (en) 2015-07-16
CA2874676A1 (en) 2013-11-28
JP6478908B2 (en) 2019-03-06
NZ702169A (en) 2016-10-28
US20170166891A1 (en) 2017-06-15
US20140154266A1 (en) 2014-06-05
EP2854865B1 (en) 2019-02-20
EP2854865A4 (en) 2016-03-02
EP2854865A2 (en) 2015-04-08
HK1209035A1 (en) 2016-03-24
CN104812898B (en) 2018-01-30
WO2013177535A8 (en) 2014-11-13
BR112014029301A2 (en) 2017-07-25
WO2013177535A2 (en) 2013-11-28
IL235910A0 (en) 2015-01-29
WO2013177535A3 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
SG11201407775WA (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201407569PA (en) Interrogatory cell-based assays for identifying drug-induced toxicity markers
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407268SA (en) Nuclear transport modulators and uses thereof
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201408651TA (en) Use of markers in the diagnosis and treatment of prostate cancer
SG11201408261UA (en) Syringe
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201809714TA (en) Piperidines as menin inhibitors
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201806861SA (en) Combination therapy with anti-cd73 antibodies
SG11201407370QA (en) Humanized il-7 rodents
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201804312RA (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201408679XA (en) Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201407561UA (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
SG11201908179UA (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
SG11201407880QA (en) Treatment of solid tumors using coenzyme q10
SG11201407890VA (en) Tetrahydropyrazolopyrimidine compounds
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201805828YA (en) Method of treating c3 glomerulopathy